Search the Newsreel

StoneX's High ROE Supports the Bull Case: Is It Sustainable?

StoneX Group (SNEX) has shown a strong return on equity (ROE) of 19.31%, significantly above the industry average, driven by heightened market volatility, strategic acquisitions, and growing client balances. However, the sustainability of this high ROE is challenged by increasing expenses, rising bad-debt costs, …

Should Investors Consider StoneX Stock After Its Impressive YTD Rally?

StoneX Group's stock (SNEX) has surged 75.7% year-to-date, outperforming peers, due to a favorable environment for brokerage stocks, heightened volatility, and an uncertain macro backdrop. The company, which operates a diversified financial services franchise, has also benefited from strategic acquisitions and investments in AI-enabled …

StoneX Group (NASDAQ:SNEX) Insider Sells $3,892,584.32 in Stock

StoneX Group (NASDAQ:SNEX) insider Mark Lowry Maurer sold 52,376 shares of the company's stock for approximately $3.89 million on July 22nd, reducing his direct ownership by 19.21%. This transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The company's stock recently traded down …

StoneX Group (NASDAQ:SNEX) Insider Diego Rotsztain Sells 29,995 Shares

StoneX Group insider Diego Rotsztain sold 29,995 shares of SNEX stock for $2.23 million, reducing his position by 35.08% under a pre-arranged Rule 10b5-1 plan. This sale is part of a larger trend where StoneX insiders, including the chairman, CFO, and CEO, sold a …

StoneX Group (NASDAQ:SNEX) CFO Sells $7,133,450.10 in Stock

StoneX Group's CFO, William Dunaway, sold 95,970 shares of the company's stock for over $7.13 million, reducing his direct holdings by 16.89%. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan. Despite the sale, StoneX shares have seen recent institutional inflows, and …

StoneX Group (SNEX) to Post Earnings on Tuesday

StoneX Group (SNEX) is scheduled to release its Q3 2026 earnings after market close on Tuesday, August 4th, with analysts expecting earnings of $0.857 per share and revenues of $1.321 billion. The company's previous quarter exceeded earnings estimates but missed revenue targets. Despite a …

BioNexus Advances VitaGuard™ Southeast Asia Rollout Following China Working Visit

BioNexus Gene Lab Corp. announced progress in commercializing its VitaGuard™ molecular residual disease (MRD) platform in Southeast Asia after a working visit to Tongshu Gene's facilities in China. The visit involved technical planning and meetings with Chinese hospitals where VitaGuard is already in commercial …

BioNexus Says VitaGuard Blood Tests Could Cost Under $300

BioNexus (BGLC) is progressing with the commercialization of its VitaGuard™ molecular residual disease (MRD) liquid-biopsy platform in Southeast Asia, targeting an initial rollout in select medical hubs in 2026. The company anticipates the cost per VitaGuard test to be under US$300, aiming to make …

StoneX Group (SNEX) legal chief sells 20,630 shares in plan trade

StoneX Group Inc.'s Chief Governance/Legal Officer, Diego Rotsztain, sold 20,630 shares of common stock on July 24, 2026, through a Rule 10b5-1 trading plan at an average price of $74.4007 per share. Following this transaction, Rotsztain retains 34,870 shares. The sale, valued at approximately …

Form 4 Stonex Group Inc For: 27 July By Investing.com

This article announces the filing of Form 4 for Stonex Group Inc. on July 27. It is a brief news item from Investing.com, accompanied by standard market data and links to related financial news and tools. The content primarily serves as a notification of …

Stonex chief governance officer sells $1.53m in stock

Diego Rotsztain, Chief Governance/Legal Officer at StoneX Group Inc. (NASDAQ:SNEX), sold 20,630 shares worth approximately $1.53 million on July 24, 2026. This insider sale follows a 77% surge in StoneX shares over the past year. The company recently surpassed earnings expectations but faced a …

BioNexus Gene Lab Corp Revenue Breakdown – NASDAQ:BGLC

BioNexus Gene Lab Corp (NASDAQ: BGLC) revenue breakdown highlights Malaysia as the primary contributor, generating $5.83 million last year, down from $7.46 million the previous year. This information is derived from their financial statements, focusing on top segments and regional performance.

SNEX|StoneX Group Inc|Price:74.260|Chg%:-0.600

This article provides a detailed introduction to StoneX Group Inc. (SNEX), outlining its global financial services network, business segments (Commercial, Institutional, Self-Directed/Retail, and Payments), and key financial data. It also lists company executives with their shareholdings and discusses institutional ownership, highlighting a significant increase …

BioNexus Gene Lab Corp (BGLC) Cash Flow

This article provides a detailed cash flow statement for BioNexus Gene Lab Corp (BGLC), including quarterly and annual data for operating, investing, and financing activities. It also defines key cash flow terms and offers insights into BGLC's financial health, such as an operating cash …

Noronex Acquires Advanced Alaska Tin-Tungsten-Silver Project

BioNexus Gene Lab Corp (BGLC) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of BioNexus Gene Lab Corp (BGLC), including major individual and corporate holders, their proportionate ownership, and recent activity. It also provides institutional shareholding data over several quarters, showing changes in the number of institutions and shares held. Key …

BGLC|BioNexus Gene Lab Corp|Price:1.613|Chg%:-0.027

BioNexus Gene Lab Corp (BGLC) is a biotechnology company specializing in precision diagnostics and chemical solutions. While the stock has seen significant declines over various periods, its fundamentals are deemed healthy with significant growth potential, and it is considered fairly valued within the Biotechnology …

Onex Corporation Revenue Breakdown – TSX:ONEX

Enterprise value to revenue forward of StoneX Group Inc. – NASDAQ:SNEX

This article from TradingView provides a financial overview of StoneX Group Inc. (NASDAQ: SNEX), specifically focusing on its enterprise value to revenue forward metric. It appears to be a stub or an introductory page for financial data, indicating that more detailed information might be …

BioNexus Gene Lab Corp (BGLC) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of BioNexus Gene Lab Corp (BGLC), noting its current valuation score of 8.43, which ranks it 138 out of 386 in the Biotechnology & Medical Research industry. It highlights the company's P/E ratio of -1.02, while also stating …

Stonex Group Inc. (SNEX) Q1 2025 Earnings Report - Results, Call & Slides

StoneX Group Inc. (SNEX) reported its Q1 2025 earnings, surpassing analyst expectations with an actual EPS of $13.18 against a consensus of $11.26 and actual revenue of $489.13 billion compared to an expected $16.02 billion. This represents a significant beat and a 42.71% year-over-year …

BGLC|BioNexus Gene Lab Corp|Price:1.510|Chg%:-0.050

BioNexus Gene Lab Corp (BGLC) is a biotechnology company specializing in precision diagnostics and chemical solutions. While the stock has seen significant declines over various periods, its fundamentals are deemed healthy with significant growth potential, and it is considered fairly valued within the Biotechnology …

BioNexus Gene Lab Corp (BGLC) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of BioNexus Gene Lab Corp (BGLC), evaluating its price momentum, support and resistance levels, and various technical indicators and moving averages. As of July 24, 2026, BGLC has a price momentum score of 4.76, trading between resistance at …

Insider Sell: Diego Rotsztain Sells 29,995 Shares of StoneX Grou

Diego Rotsztain, Chief Governance/Legal Officer at StoneX Group Inc, sold 29,995 shares on July 22, 2026, reducing his holdings to 55,500 shares. This transaction is part of a pattern where Rotsztain has sold a total of 69,599 shares over the past year with no …

Stonex group chief risk officer Mark Maurer sells $3.89m in stock

Mark Maurer, Chief Risk Officer at StoneX Group Inc. (NASDAQ:SNEX), sold 52,376 shares of company common stock worth approximately $3.89 million on July 22, 2026. This sale followed his acquisition of 69,372 shares through the exercise of stock options. StoneX Group recently reported strong …

StoneX Group CEO Philip Smith sells $3.34m in company stock

StoneX Group CEO Philip Smith sold 45,000 shares of company stock for approximately $3.34 million after exercising stock options. This sale follows a significant surge in StoneX shares year-to-date and comes amid other company developments, including strong Q2 earnings, a stock split, and expansion …

StoneX Group Inc. (SNEX) CRO sells 52,376 shares after major option exercise

StoneX Group Inc.'s Chief Risk Officer, Mark Lowry Maurer, exercised stock options to acquire 69,372 shares at $8.90 per share and subsequently sold 52,376 shares at an average price of $74.3218 per share on July 22, 2026, under a Rule 10b5-1 trading plan. After …

StoneX Group (SNEX) CEO exercises options, sells 45,000 shares

StoneX Group Inc. CEO Philip Andrew Smith reported exercising options for 45,000 shares and subsequently selling all 45,000 common shares at an average price of $74.3218 on July 22, 2026. These transactions were executed under a Rule 10b5-1 trading plan. After the sale, Smith …

StoneX Group (SNEX) leader exercises options and sells over 100K shares

Sean Michael O’Connor, Executive Vice-Chairman of StoneX Group Inc. (SNEX), exercised stock options to acquire 225,000 shares at $8.90 per share and subsequently sold 104,934 shares at an average price of $74.3303 per share under a Rule 10b5-1 trading plan. After these transactions, O'Connor …

Euronext announces the cancellation of repurchased shares

Euronext Paris SA Euronext announces the cancellation of repurchased shares Amsterdam, Athens, Brussels, Dublin, Lisbon, Milan, Oslo and Paris – 23 July 2026 – Euronext today announced the cancellation of 1,967,993 ordinary shares following completion of its €250 million share repurchase programme on 27 …

SNEX (SNEX) investor files to sell 95,970 common shares via Merrill Lynch

An investor in StoneX Group Inc. (SNEX) has filed a Form 144 to sell 95,970 common shares through Merrill Lynch, with an anticipated sale date of July 22, 2026. This planned sale is related to Stock Plan Activity. Additionally, the filing reports previous sales …

SNEX (SNEX) insider Sean O’Connor may sell 104,934 common shares

Sean O'Connor, an insider at StoneX Group Inc. (SNEX), has filed a Form 144 indicating his intention to sell up to 104,934 shares of common stock through Merrill Lynch on July 22, 2026. The filing also details O'Connor's previous sales of SNEX common stock …

Is Jefferies’ Capital Markets Downgrade Altering The Investment Case For StoneX Group (SNEX)?

Jefferies downgraded StoneX Group due to concerns about its capital markets outlook, leading to a significant 33.5% share price drop. This downgrade puts StoneX's capital markets segment, previously a key growth catalyst, under scrutiny, although the company's strong earnings trajectory suggests the selloff might …

Form 4 Stonex Group Inc For: 21 July By Investing.com

This article announces the filing of Form 4 for Stonex Group Inc. on July 21. It is a brief news item from Investing.com, typical of filings made public through the SEC. The article itself contains minimal information beyond the headline and company mention, serving …

StoneX CIO Abigail Perkins sells $628k in shares at $70.43

StoneX CIO Abigail Perkins sold 8,919 shares of StoneX Group Inc. for approximately $628,147 at an average price of $70.428 per share. This sale comes as the company's stock has seen a 76% year-to-date surge. Following the transaction, Perkins directly holds 96,663 shares.

StoneX Group Inc. (SNEX) CIO sells 8,919 shares under 10b5-1 plan

StoneX Group Inc.'s Chief Information Officer, Abigail H. Perkins, sold 8,919 shares of common stock on July 20, 2026, for an average price of $70.428 per share under a Rule 10b5-1 trading plan. Following this transaction, Perkins directly holds 96,663 shares and indirectly holds …